Claims for Patent: 6,395,728

Summary for Patent: 6,395,728

Title:	Method of treatment and pharmaceutical composition
Abstract:	The invention relates to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, myocardial infarction and its sequelae, supraventricular and ventricular arrhythmias, atrial fibrillation or atrial flutter, atherosclerosis, angina (whether stable or ustable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetessecondary aldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and pulmonary hypertension, renal failure conditions, such as diabetic nephropathy,glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), and stroke, comprising administering a therapeutically effective amount of combination of (i) the AT.sub.1 -antagonists valsartan or a pharmaceutically acceptable salt thereof and (ii) a Calcium channel blocker or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a mammal in need of such treatment and to corresponding pharmaceutical combination composition.
Inventor(s):	Webb; Randy Lee (Flemington, NJ), de Gasparo; Marc (Es Planches, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	09/757,413
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,395,728
Patent Claims:	1. A method for the treatment or prevention of hypertension associated with diabetes comprising administering a therapeutically effective amount of a combination consisting essentially of (i) the AT.sub.1 -antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) the Calcium channel blocker amlodipine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier to a mammal in need thereof. 2. A pharmaceutical combination composition consisting essentially of (i) the AT.sub.1 -antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) the Calcium channel blocker amlodipine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 3. A pharmaceutical combination composition as claimed in claim 2 for oral application, comprising of about 10 mg to about 200 mg of valsartan. 4. A pharmaceutical combination composition as claimed in claim 2 for oral application, comprising about 1.0 mg to about 180 mg of the Calcium channel blocker amlodipine.